Using Harmonic Scalpel to Reduce Drainage After Lung Surgery
Use of Harmonic Scalpel to Decrease Lymphatic and Chest Tube Drainage After Lymph Node Dissection With Lobectomy. A Single Center Prospective Randomized Controlled Study.
This study is testing if using a special tool called the Harmonic Scalpel during lung cancer surgery can help reduce drainage and the need for chest tubes, making recovery easier for patients.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 20 Years to 75 Years |
| Sex | All |
| Sponsor | Sentara Cardiovascular Research Institute Academic / other |
| Locations | 1 site (Norfolk, Virginia) |
| Trial ID | NCT00591552 on ClinicalTrials.gov |
What this trial studies
This study investigates whether the Harmonic Scalpel can effectively reduce lymphatic drainage and the need for chest tubes after lymph node dissection in lung cancer surgeries. Patients undergoing resection for stage 1, 2, or 3A lung cancer will be randomly assigned to receive either the Harmonic Scalpel or traditional electrocautery during their procedure. The primary goal is to determine if the Harmonic Scalpel leads to less drainage and shorter hospital stays compared to the control method. The study aims to provide evidence for the potential benefits of using this newer technology in surgical oncology.
Who should consider this trial
Good fit: Ideal candidates are patients aged 20-75 with stage 1, 2, or 3A lung cancer who are scheduled for surgical resection.
Not a fit: Patients with a history of congestive heart failure, renal failure, bulky lymph nodes, or those who are pregnant may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to shorter hospital stays and improved recovery for lung cancer patients undergoing surgery.
How similar studies have performed: While there is no published data specifically supporting the use of the Harmonic Scalpel in this context, similar studies have shown promising results with advanced surgical techniques.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients undergoing resection for stage 1, 2 or 3A lung cancer. * Patients between the ages of 20-75. Exclusion Criteria: * History of Congestive Heart Failure. * History of renal failure, ie., creatinine greater than 2.2. * Patients with bulky or matted lymph nodes in stage 3A. * Current pregnancy. * Current participation in another study involving an investigational device or drug.
Where this trial is running
Norfolk, Virginia
- Sentara Norfolk General Hospital/Sentara Heart Hospital — Norfolk, Virginia, United States (Recruiting)
Study contacts
- Principal investigator: Joseph Newton, MD — Sentara Cardiovascular Research Institute
- Study coordinator: Laura Pine, RN, BSN
- Email: ljpine@sentara.com
- Phone: 757-388-2732
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.